Mostrando 3 resultados de: 3
A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients
ArticleAbstract: Purpose: Racotumomab-alum is an anti-idiotype vaccine targeting the NeuGcGM3 tumor-associated gangliPalabras claves:Autores:Alfonso S., Areces F., Carmen Elena Viada, Cepeda M., Chong E., De La Torre A.V., Flores Y.I., García E., Gonzalez Z., Guerra P.P., Hernández A.M., Hernández M., Macías A.E., Mazorra Z., Mendoza I.C., Ortiz R.A., Pérez K., Pérez R., Santiesteban E.R., Tania Crombet, Toledo D., Valdes-Zayas A., Vázquez A.M.Fuentes:scopusImmunologic Response Elicited in Breast Cancer Patients Receiving a NeuGcGM3-based Vaccine as Adjuvant Therapy
ArticleAbstract: This study aimed to investigate the immunogenicity of a cancer vaccine consisting of the NeuGcGM3 gaPalabras claves:adjuvant therapy, Breast Cancer, cytotoxic antibodies, Ganglioside, NeuGcGM3, VaccineAutores:Curbelo I., Estevez A., Fernandez L.E., Gonzalez Z., Luaces P.L.o., Mazorra Z., Mulens V., Pérez K., Rubio M.C., Tania Crombet, Valdes-Zayas A., Vega A.M.Fuentes:scopusImmunological evaluation of rheumatoid arthritis patients treated with itolizumab
ArticleAbstract: Rheumatoid arthritis is an autoimmune disease characterized by joint inflammation that affects approPalabras claves:Anti-idiotypic antibody response, Itolizumab, Peripheral lymphocytic counts, Proinflammatory cytokines, Rheumatoid ArthritisAutores:Aira L.E., Carmen Elena Viada, Chico A., Fuentes K.P., Gómez J.A., Gonzalez Z., Hernández P., Mazorra Z., Prada D.M.Fuentes:scopus